Peptide-binding assays and HLA II transgenic Aβ° mice are consistent and complementary tools for identifying HLA II-restricted peptides

Vaccine

Volumn 24, Issue 13, 2006, Pages 2225-2229

  Depil, Stéphane ^a,b   Angyalosi, Gerhild ^a   Moralès, Olivier ^a   Delacre, Myriam ^a   Delhem, Nadira ^a   François, Violaine ^a   Georges, Bertrand ^a   Hammer, Juergen ^c   Maillère, Bernard ^d   Auriault, Claude ^a   Pancré, Véronique ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c HOFFMANN LA ROCHE INC   (United States)

^d CEA SACLAY   (France)

Author keywords

Binding assays; MHC class II; Peptide; Transgenic mice; Vaccine

Indexed keywords

ALANYLTRYPTOPHANYLLEUCYLGLUTAMYLALANYLGLUTAMINYLGLUTAMYLGLUTAMYLGLUTAMYL GLUTAMYLVALYLGLYCYLPHENYLALANINE; EPITOPE; GLUTAMYLASPARAGINYLLEUCYLLEUCYLALANYLSERYLSERYLARGINYLPROLYLLEUCYLALANYL LYSYLTYROSYLLEUCYLSERYLASPARAGINYLARGINYLPROLYLALANYLTHREONYLPROLYL PHENYLALANIN E; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; LIGAND BINDING; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SCHISTOSOMA MANSONI; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, BACTERIAL; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, NEF; GENES, MHC CLASS II; GLUTATHIONE TRANSFERASE; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; VACCINES;

EID: 33344462487     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.11.048     Document Type: Article

References (29)

1. P. Chaux, V. Vantomme, V. Stroobant, K. Thielemans, J. Corthals, and R. Luiten Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes J Exp Med 189 5 1999 767 778
2. C.L. Day, G.M. Lauer, G.K. Robbins, B. McGovern, A.G. Wurcel, and R.T. Gandhi Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection J Virol 76 24 2002 12584 12595
3. A. Leen, P. Meij, I. Redchenko, J. Middeldorp, E. Bloemena, and A. Rickinson Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses J Virol 75 18 2001 8649 8659
4. T. Sturniolo, E. Bono, J. Ding, L. Raddrizzani, O. Tuereci, and U. Sahin Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices Nat Biotechnol 17 6 1999 555 561
5. S. Manici, T. Sturniolo, M.A. Imro, J. Hammer, F. Sinigaglia, and C. Noppen Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T-cells in association with histocompatibility leukocyte antigen DR11 J Exp Med 189 5 1999 871 876
6. S. Kruger, R. Schroers, C.M. Rooney, B. Gahn, and S.Y. Chen Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1 J Immunother 26 3 2003 212 221
7. G. Consogno, S. Manici, V. Facchinetti, A. Bachi, J. Hammer, and B.M. Conti-Fine Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3 Blood 101 3 2003 1038 1044
8. C. Texier, S. Pouvelle, M. Busson, M. Herve, D. Charron, and A. Menez HLA-DR restricted peptide candidates for bee venom immunotherapy J Immunol 164 6 2000 3177 3184
9. K. Yamamoto, Y. Fukui, Y. Esaki, T. Inamitsu, T. Sudo, and K. Yamane Functional interaction between human histocompatibility leukocyte antigen (HLA) class II and mouse CD4 molecule in antigen recognition by T-cells in HLA-DR and DQ transgenic mice J Exp Med 180 1 1994 165 171
10. A. Geluk, V. Taneja, K.E. van Meijgaarden, E. Zanelli, C. Abou-Zeid, and J.E. Thole Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice Proc Natl Acad Sci USA 95 18 1998 10797 10802
11. G. Sonderstrup, A.P. Cope, S. Patel, M. Congia, N. Hain, and F.C. Hall HLA class II transgenic mice: models of the human CD4+ T-cell immune response Immunol Rev 172 1999 335 343
12. C.E. Touloukian, W.W. Leitner, S.L. Topalian, Y.F. Li, P.F. Robbins, and S.A. Rosenberg Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice J Immunol 164 7 2000 3535 3542
13. V. Pancré, B. Georges, G. Angyalosi, F. Castelli, A. Delanoye, and M. Delacre Novel promiscuous HLA-DQ HIV Nef peptide that induces IFN-gamma-producing memory CD4+ T-cells Clin Exp Immunol 129 3 2002 429 437
14. J.M. Rojas, S.E. McArdle, R.B. Horton, M. Bell, S. Mian, and G. Li Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53 Cancer Immunol Immunother 54 3 2005 243 253
15. A. Pajot, V. Pancré, N. Fazilleau, M.L. Michel, G. Angyalosi, and D.M. Ojcius Comparison of HLA-DR1-restricted T-cell response induced in HLA-DR1 transgenic mice deficient for murine MHC class II and HLA-DR1 transgenic mice expressing endogenous murine MHC class II molecules Int Immunol 16 9 2004 1275 1282
16. Gausepohl H, Kraft M, Boulin C, Frank RW. Frmoc solid phase peptide synthesis. In: Proceedings of the 11th American Peptide Symposium. Leiden: ESCOM, 1990. p. 1003-4.
17. J.C. Gorga, V. Horejsi, D.R. Johnson, R. Raghupathy, and J.L. Strominger Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line J Biol Chem 262 33 1987 16087 16094
18. V. Taneja, and C.S. David HLA transgenic mice as humanized mouse models of disease and immunity J Clin Invest 101 5 1998 921 926
19. E.F. Rosloniec, D.D. Brand, L.K. Myers, K.B. Whittington, M. Gumanovskaya, and D.M. Zaller An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen J Exp Med 185 6 1997 1113 1122
20. D. Cosgrove, D. Gray, A. Dierich, J. Kaufman, M. Lemeur, and C. Benoist Mice lacking MHC class II molecules Cell 66 5 1991 1051 1066
21. V. Pancré, M. Delacre, J. Herno, and C. Auriault Schistosomal egg antigen-responsive CD8 T-cell population in Schistosoma mansoni-infected BALB/c mice Immunology 98 4 1999 525 534
22. S. Southwood, J. Sidney, A. Kondo, M.F. del Guercio, E. Appella, and S. Hoffman Several common HLA-DR types share largely overlapping peptide-binding repertoires J Immunol 160 7 1998 3363 3373
23. F.A. Castelli, C. Buhot, A. Sanson, H. Zarour, S. Pouvelle-Moratille, and C. Nonn HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity J Immunol 169 12 2002 6928 6934
24. A. Scardino, D.A. Gross, P. Alves, J.L. Schultze, S. Graff-Dubois, and O. Faure HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy J Immunol 168 11 2002 5900 5906
25. D.A. Gross, S. Graff-Dubois, P. Opolon, S. Cornet, P. Alves, and A. Bennaceur-Griscelli High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy J Clin Invest 113 3 2004 425 433
26. G.H. Nabozny, J.M. Baisch, S. Cheng, D. Cosgrove, M.M. Griffiths, and H.S. Luthra HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis J Exp Med 183 1 1996 27 37
27. V. Pancré, I. Wolowczuk, M. Bossus, H. Gras-Masse, S. Guerret, and A. Delanoye Evaluation of the effect of Sm28GST-derived peptides in murine hepatosplenic schistosomiasis: interest of the lipopeptidic form of the C-terminal peptide Mol Immunol 31 16 1994 1247 1256
28. V. Pancré, H. Gras-Masse, A. Delanoye, J. Herno, A. Capron, and C. Auriault Induction of cytotoxic T-cell activity by the protective antigen of Schistosoma mansoni Sm28GST or its derived C-terminal lipopeptide Scand J Immunol 44 5 1996 485 492
29. A. Pajot, M.L. Michel, N. Fazilleau, V. Pancré, C. Auriault, and D.M. Ojcius A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice Eur J Immunol 34 11 2004 3060 3069